Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Drug Discov Devel. 2005 Jul;8(4):487-94.

High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics.

Author information

  • Pfizer Global Research and Development, New Leads Biology: Exploratory Medicinal Sciences, Groton Laboratories, MS-8118W-110, Eastern Point Road, Groton,CT 06340, USA. bruce.a.posner@pfizer.com

Abstract

The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.

PMID:
16022185
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk